Sleep Disorders
7 videos · updated daily
19:53 Anti-Inflammatory Trial in Prodromal Parkinson's
Professor Simon Lewis summarises his International Parkinson and Movement Disorder Society presentation on a double-blind trial that randomised 41 people with isolated REM sleep behaviour disorder to a Syntara small molecule or placebo.
1:20 Oveporexton for Narcolepsy Type 1: Phase 3 Results
NEJM Group summarises results from the phase 3 First Light and Radiant Light trials, in which oveporexton improved wakefulness and reduced daytime sleepiness and cataplexy in patients with narcolepsy type 1.
7:02 Narcolepsy Approval, a SYNGAP1 Trial and a Phase 3 Exit
CheckRare covers FDA approval of Takeda's Orzeyful (oveporexton) for narcolepsy type 1, CAMP4's plan in August 2026 to take CMP-002 into a first-in-human Phase 1/2 trial in SYNGAP1-related disorders, and BioMarin ending an ENPP1 programme after Phase 3.
53:52 The TIME Trial: Does Immunotherapy Timing Matter in Melanoma?
Dr. Omid Hamid of The Angeles Clinic, Dr. Ryan Sullivan of Massachusetts General Hospital and colleagues explain the TIME Trial, testing whether earlier-in-the-day immunotherapy affects outcomes in advanced melanoma, for the Melanoma Research Alliance.
A Platform Trial for Progressive Supranuclear Palsy
Julio Rojas, MD, PhD, a neurologist at the UCSF Memory and Aging Center, tells NeurologyLive how a platform trial in progressive supranuclear palsy could speed the evaluation of potential disease-modifying therapies.
3:12 Takeda's Sara Sarkey on the Oveporexton Approval
Sara Sarkey, PhD, vice president of Neuroscience and Vaccines at Takeda, tells NeurologyLive about the clinical significance of the FDA approval of oveporexton for narcolepsy type 1 and how restoring orexin signalling may change treatment expectations.
44:27 Knowledge Graphs and GenAI in Clinical Trial Programming
Karl Brand of Bayer, in a Verisian presentation, discusses the challenges of clinical trial data programming and how knowledge graphs and large language models could speed regulatory submissions.